QNTM Quantum Biopharma Ltd.
Price Chart
Executive Summary
Quantum Biopharma reported its 2025 audited financial results, showing improved financial health with $11.3 million in cash and digital assets, reduced operating expenses and payables, and no going concern issues. The company made progress on its MS drug candidate Lucid-MS, completing Phase 1 toxicity studies and advancing toward a Phase 2 trial, while also achieving a peer-reviewed publication for its alcohol metabolism product unbuzzd and securing a Canadian product license for Qlarity. A board member resigned, and Unbuzzd launched a $5M private offering in preparation for a potential IPO.
Actionable Insight
Investors should monitor the upcoming IND filing for Lucid-MS Phase 2 trial and any progress on Unbuzzd's IPO plans, which could unlock significant value. The strong cash runway and reduced liabilities reduce near-term dilution risk, making QNTM a less speculative hold with multiple potential catalysts in 2026.
Key Facts
- Cash on hand and fair market value of digital assets: $11.3 million USD as of filing date
- Operating expenses decreased to $15.3 million in 2025 from $16.1 million in 2024 (-5%)
- Trade and other payables reduced by ~50%, from $4.1 million to $2.0 million
- External R&D fees dropped to $2.8 million from $6.1 million due to completion of Phase 1 trials and Australian R&D tax credits
- Phase 1 oral toxicity studies for Lucid-MS completed with no significant side effects; IND filing planned for H1 2026
- Peer-reviewed publication confirmed unbuzzd accelerates BAC reduction and reduces hangover symptoms
- Health Canada granted product license for Qlarity, allowing Canadian sales
- Unbuzzd launched $5.0 million Regulation D offering and is preparing for IPO; Quantum holds 19.84% stake and will not be diluted
- All hedge fund warrants expired in 2025; special dividend of CVRs distributed October 27, 2025
- Terry Lynch resigned from board effective March 27, 2026
Financial Impact
Cash position of $11.3 million supports operations beyond January 2028; $5.0 million Unbuzzd offering could generate non-dilutive proceeds for Quantum upon monetization. R&D cost savings of $3.3 million year-over-year improved efficiency.
Risk Factors
- Biotech development risk: Lucid-MS is still pre-revenue and must succeed in Phase 2 trials
- Unbuzzd IPO and financing are not guaranteed and depend on market conditions
- Litigation against CIBC and RBC is ongoing with uncertain outcome
- Company relies on future monetization events that are forward-looking and not assured
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-001969 |
| Document: f6k_032626.htm | 0001171843-26-001969 |
| Document: 0001171843-26-001969-index-headers.html | 0001171843-26-001969 |
| Document: 0001171843-26-001969-index.html | 0001171843-26-001969 |
| Document: 0001171843-26-001969.txt | 0001171843-26-001969 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
12d ago
|
6-K
| $5.11 $4.88 | ▲ +4.50% | ▲ +3.81% | $3.83 (+25.05%) |
|
Jun 2, 2026
12d ago
|
6-K
| $5.11 $4.88 | ▼ −4.50% | ▼ −3.78% | $3.83 (−25.05%) |
|
May 18, 2026
27d ago
|
6-K
| $6.27 $7.00 | ▲ +11.64% | ▲ +12.29% | $3.83 (−38.92%) |
|
Apr 22, 2026
7w ago
|
6-K
| $3.35 $3.21 | ▼ −4.18% | ▼ −3.79% | $3.83 (+14.33%) |
|
Apr 22, 2026
7w ago
|
Press Release
| $3.35 $3.21 | ▼ −4.18% | ▼ −3.79% | $3.83 (+14.33%) |
|
Apr 2, 2026
10w ago
|
6-K
| $3.98 $3.58 | ▼ −10.05% | ▼ −10.53% | $3.83 (−3.77%) |
|
Apr 1, 2026
10w ago
|
6-K
| $4.41 $3.98 | ▼ −9.75% | ▼ −9.83% | $3.83 (−13.15%) |
|
Apr 1, 2026
10w ago
|
Press Release
| $4.41 $3.98 | ▼ −9.75% | ▼ −9.83% | $3.83 (−13.15%) |
|
Mar 30, 2026
11w ago
|
Court Ruling
| $4.28 $4.83 | ▲ +12.85% | ▲ +9.96% | $3.83 (−10.51%) |
|
Mar 27, 2026
11w ago
|
6-K
| $4.77 $4.28 | ▼ −10.27% | ▼ −9.91% | $3.83 (−19.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access